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Research | Environmental Medicine
Chronic Beryllium Disease and Sensitization at a Beryllium Processing
Facility
Kenneth Rosenman,1 Vicki Hertzberg,2 Carol Rice,3 Mary Jo Reilly,1 Judith Aronchick,4 John E. Parker,5
Jackie Regovich,4 and Milton Rossman 4
1Michigan

State University, East Lansing, Michigan, USA; 2Emory University, Atlanta, Georgia, USA; 3University of Cincinnati,
Cincinnati, Ohio, USA; 4University of Pennsylvania, Philadelphia, Pennsylvania, USA; 5West Virginia University, Morgantown,
West Virginia, USA

We conducted a medical screening for beryllium disease of 577 former workers from a beryllium
processing facility. The screening included a medical and work history questionnaire, a chest radiograph, and blood lymphocyte proliferation testing for beryllium. A task exposure and a job exposure matrix were constructed to examine the association between exposure to beryllium and the
development of beryllium disease. More than 90% of the cohort completed the questionnaire, and
74% completed the blood and radiograph component of the screening. Forty-four (7.6%) individuals had definite or probable chronic beryllium disease (CBD), and another 40 (7.0%) were sensitized to beryllium. The prevalence of CBD and sensitization in our cohort was greater than the
prevalence reported in studies of other beryllium-exposed cohorts. Various exposure measures
evaluated included duration; first decade worked; last decade worked; cumulative, mean, and highest job; and highest task exposure to beryllium (to both soluble and nonsoluble forms). Soluble
cumulative and mean exposure levels were lower in individuals with CBD. Sensitized individuals
had shorter duration of exposure, began work later, last worked longer ago, and had lower cumulative and peak exposures and lower nonsoluble cumulative and mean exposures. A possible
explanation for the exposure–response findings of our study may be an interaction between
genetic predisposition and a decreased permanence of soluble beryllium in the body. Both CBD
and sensitization occurred in former workers whose mean daily working lifetime average exposures were lower than the current allowable Occupational Safety and Health Administration
workplace air level of 2 µg/m3 and the Department of Energy guideline of 0.2 µg/m3. Key words:
beryllium, chronic beryllium disease, epidemiology, exposure–response, lymphocyte proliferation
testing. Environ Health Perspect 113:1366–1372 (2005). doi:10.1289/ehp.7845 available via
http://dx.doi.org/ [Online 26 May 2005]

Researchers early on recognized that chronic
beryllium disease (CBD) occurred after both
high and low levels of exposure and hypothesized that the disease was immunologically
mediated (Sterner and Eisenbud 1951).
Subsequent work has confirmed the importance of cellular immunity to beryllium in the
pathogenesis of CBD (Rossman 2001). The
factors that determine why some individuals
develop cellular immunity to beryllium while
others do not still need to be elucidated.
Medical screenings of beryllium-exposed
workers consistently demonstrate that a larger
percentage of individuals will have a positive
blood lymphocyte proliferation test to beryllium (become sensitized) than will be diagnosed with CBD (sensitization and granuloma
in lung parenchyma) (Henneberger et al.
2001; Kelleher et al. 2001; Kreiss et al. 1993a;
Stange et al. 2001). It is not known what proportion of individuals who are sensitized to
beryllium will progress to develop CBD.
Furthermore, there is a varied clinical presentation of patients with CBD and variability in
its progression (Newman et al. 1996;
Rossman et al. 1999).
The current occupational air standard for
beryllium, ﬁrst proposed in 1951, was based
on the toxicity of other metals such as arsenic,
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lead, and mercury and modified to reflect
beryllium’s lower atomic weight and concern
about its greater toxicity (Eisenbud 1982).
Epidemiologic health outcome and exposure
studies were not used to develop the initial
time-weighted average permissible exposure
level of 2 µg/m3. Fifty years later, this remains
the current air level that Occupational Safety
and Health Administration (OSHA) enforces
in the workplace.
Recent studies looking at beryllium disease
and exposure have either used a surrogate of
exposure (i.e., months of exposure, percent
exposed to unﬁred beryllium oxide) or calculated exposure metrics and found increased
disease with some parameters of increased
exposure (Henneberger et al. 2001; Kelleher
et al. 2001; Kreiss et al. 1993b, 1997; Viet
et al. 2000). One study found an exposure–
response relationship for sensitization with
CBD but not for sensitization without CBD
(Viet et al. 2000). Other work has addressed
the possibility of particle size (McCawley et al.
2001), skin absorption (Tinkel et al. 2003),
and/or genetic susceptibility (Saltini et al.
2001) as important factors that confound a
straightforward exposure–response relationship.
We investigated possible exposure–
response relationships separately for various
VOLUME

measures of exposure, including mean, peak,
and cumulative metrics and differing chemical and physical forms for the development of
beryllium sensitization and for the development of CBD.
We have also assessed whether the current
OSHA (2005) and Department of Energy
(DOE 1999) permissible levels were protective against the development of CBD and
sensitization.

Materials and Methods
The cohort was composed of workers from a
beryllium production facility in eastern
Pennsylvania, which operated from 1957 to
1978. The names of former workers with at
least 2 days of work up to 31 December 1969
who had previously been identiﬁed from personnel records and matched with Social
Security Administration Form 941 records by
the National Institute for Occupational Safety
and Health (NIOSH), as part of a seven-company mortality study, were obtained from
NIOSH (Ward et al. 1992). The last owner of
the facility provided the names of workers,
social security numbers, demographic information, and the last known address of all individuals who began work from 1 January 1970
until the plant closed in 1978.
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MI 48824-1316 USA. Telephone: (517) 353-1846.
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Because this study was a cooperative
effort with NIOSH, addresses from the last
income tax filing of members of the cohort
were obtained by NIOSH from the Internal
Revenue Service. NIOSH had previously
ascertained the vital status of the cohort as of
31 December 1988 using the Social Security
Administration, the Internal Revenue Service,
post office cards mailed to the last known
address, the Department of Veterans Affairs,
the Health Care Finance Administration, and
the National Death Index (Ward et al.
1992).
We mailed the initial invitation to participate in the medical screening program to the
last known address of all members of the cohort
not known to be deceased as of 31 December
1988. The mailing included a cover letter about
the study, a fact sheet about beryllium, a onepage two-sided questionnaire, and a postagepaid envelope. The questionnaire requested
demographic information and had questions
about previous lung disease, smoking history,
and work history at the beryllium facility.
We attempted to contact everyone who
did not return the questionnaire. This
included multiple phone contacts or actual
visits to the person’s home if telephone contact was unsuccessful. Internet address searches
using search engines such as Yahoo! and
Netscape were performed to locate current
mailing addresses of individuals with returned
mailings. In addition, we used the Social
Security Death Index (Ancestry.com 2005) to
help determine vital status of individuals.
Local staff in the two communities not only
made visits to last known addresses but also
asked the long-term workers to assist in identifying individuals who could not be located.
All individuals located, whether or not
they participated in the medical screening or
completed a questionnaire, received a subsequent mailing summarizing the results of the
screening and notiﬁcation of federal legislation
passed in the fall of 2000 that provided compensation for workers with CBD and coverage
for medical costs for follow-up of workers
with beryllium sensitization from this facility.
All individuals located had the opportunity
to have a blood lymphocyte proliferation test
for beryllium (BeLPT), a posterior–anterior
chest radiograph, and simple spirometry.
Before the testing, we obtained consent to conduct testing from the individual. In addition,
each participant completed a questionnaire on
other work exposures that might contribute to
respiratory deficiencies. This included other
possible sources of beryllium exposure as well
as exposure to asbestos, coal, and silica.
Medical testing was performed at two primary sites in the community in eastern
Pennsylvania. For individuals who had moved
to other parts of the country, medical testing
was performed in a location convenient to the
Environmental Health Perspectives

individual (i.e., personal physician, local medical centers, etc.).
Blood was collected Monday through
Thursday and shipped for next morning
delivery. All blood was processed the next day
and analyzed. All BeLPT was performed at
the University of Pennsylvania. Any individual with a positive BeLPT test was offered a
repeat test. If an individual’s results were
negative on the repeat test, then the individual was offered the opportunity to repeat the
blood test 1 year later.
A panel of three “B” readers interpreted all
chest radiographs. One B reader was a radiologist (J.A.), one a pulmonologist (J.E.P.), and
one an internist and occupational medicine
physician (K.R.). At least two B readers had to
classify a radiograph with ≥ 1/0 profusion in
order for a radiograph to be classiﬁed as positive for parenchymal disease.
Any individual who had two positive
BeLPTs and/or a consensus chest radiograph
reading of ≥ 1/0 for profusion was referred to
the University of Pennsylvania for follow-up
testing, which consisted of a posterior–anterior
chest radiograph, a BeLPT, an electrocardiogram, a complete medical history including
respiratory symptoms using a standardized
collection instrument, and bronchoscopy with
both bronchial biopsy and lymphocyte testing
of lavage fluid for beryllium. All bronchoscopies were performed by a single pulmonologist (M.R.).
Whether or not an individual had CBD
or beryllium sensitization was decided by consensus by the internist/occupational physician
(K.R.) and pulmonologist (M.R.). Table 1
outlines the criteria used to categorize the
medical testing results. However, only individuals who had bronchoscopy were used in
the analysis describing the predictive power of
radiographs or BeLPT.
All individuals received a letter with the
results of their initial screening and, where
applicable, a letter with the results of the

follow-up testing. The Human Subject Review
Boards of Emory University, Michigan State
University, the University of Cincinnati, and
the University of Pennsylvania approved this
study.
Through discussions with long-term production and management employees, we identified major changes in the process and
engineering/work practice controls. Trends in
the exposures over time were evaluated in relation to dates of process changes and visually
from plots of the data to identify other time
points at which exposure measurements indicated a change in conditions.
Exposure had been monitored at the facility
using a method that combined the concentration at each task performed by a worker,
weighted by the duration in the shift of that
task; the products of concentration and duration at all tasks performed as part of a job were
summed and divided by the duration to the
shift. This final value was called the daily
weighted average (DWA) exposure. Data accumulated over the operating history of the plant
were identiﬁed and computerized. Using this
information, a task exposure matrix (TEM) and
a job exposure matrix (JEM) were constructed
(Chen 2001). Task-related exposure measurements were available for two time periods,
1957–1962 and 1971–1976. Because the data
most closely followed a log-normal distribution,
the geometric mean was calculated for each
task-year combination. For years with no measurements, we estimated exposures by interpolating between the previous and subsequent
values. For example, if measurements were
available for 1957, 1958, and 1959 but not for
1960, the 1959 value was entered into the
TEM. The plant history was used to develop a
strategy for imputing values from 1963 to
1971. We used the mean of task estimates for
1962 and 1971 for the period 1963–1969;
because of the engineering changes in 1970, the
1971 values were used for 1970. Estimates for
1976 were used for the remaining years of

Table 1. Criteria for beryllium disease categories.
Disease category
CBD
Probable CBD
Possible CBD
Sensitization

Possible sensitization

Bronchial
lavage

Biopsy
granuloma

+ BAL LPT
Not done
Not done
+ BAL LPT
Not done
Not done
Not done

Positive
Positive
Positive

– BAL LPT
+ BAL LPT
Not done

Negative
Negative

Chest radiograph

Blood LPT

Spirometry

Two + LPTs
Upper lobe fibrosis
Upper lobe fibrosis
Upper lobe fibrosis
Upper lobe fibrosis
Upper lobe fibrosis
Normal
Normal
Lower or midlobe
fibrosis or normal

Two + LPTs
– LPT
Single + LPT
and no retest
Two + LPTs
Two + LPTs

Normal
Normal
Normal

Single + LPT and
no retest or – LPT
retests

Abbreviations: –, negative; +, positive; BAL, bronchoalveolar lavage; LPT, lymphocyte proliferation test.
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plant operation, based on employee interviews.
For tasks never measured, the task in the same
work area most similar to the unmeasured task
was identiﬁed with the assistance of long-term
employees; the exposure value for the measured task was entered into the TEM for the
unmeasured task.
We completed the JEM by ﬁrst calculating
the geometric mean exposure for each year in
which at least one DWA measurement was
available. Exposure estimates for job–year combinations without measurements were estimated based on the plant history of engineering
changes. In the absence of information showing
production or control technology changes in
years before or after measurement data, the
measurements were assumed valid and
extended to the empty cells in the JEM. Where
increases or decreases in exposure were justiﬁed
from the plant history, we used analysis of variance (ANOVA) to evaluate the signiﬁcance of
the change in exposure. Where statistically signiﬁcant changes were identiﬁed, the new value
was entered into the cell of the JEM.
For 39 of the 130 job titles, no measurements were available for the job in any year.
For each of these jobs, we used information
from the long-term workers to identify the
job with tasks most similar to it with measurements. The time–activity pattern needed
for the evaluation of exposure was developed
and used to calculate a DWA estimate of
exposure using data in the TEM.
The values were reviewed by a group of
long-term employees who represented experience in all production areas of the facility,
maintenance, and management. They were
speciﬁcally asked to review the relative exposure values for production areas. For example,
the exposure estimated for the fluoride furnace operator is slightly higher than the
helper; this was confirmed to be correct
because the helper stood away from the
furnace and supplied materials to the perimeter only. The involvement of the group of
Table 2. Summary of cohort participation.
No. (%)
Cohort
1,351
Deceased
330 (24.4)
Unable to locate
146 (10.8)
Contacted
875
Denied ever working at facility
160 (11.8)
Potential participants
715
Medical testing
653 (91.3)
Questionnaire only
79
Questionnaire and blood
22
Questionnaire and chest radiograph
6
Questionnaire, chest radiograph, and blood 71
Questionnaire, chest radiograph, and PFTs 12
Questionnaire, PFTs, and blood
6
All components (questionnaire,
chest radiograph, blood, and PFTs)
457
Refusals
62 (8.7)
PFT, pulmonary function test.
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long-term employees provided added confidence in our derived estimates.
The JEM and TEM were linked through
the listing of the tasks in each job taken from
the DWA calculation sheets. For jobs never
sampled, the association was through the
time–activity information developed with the
help of long-term employees and, ﬁnally, put
into DWA format.
For every job title in the JEM, the chemical and physical form of the exposure was
listed. Chemical forms included beryl ore,
beryllium metal, beryllium ﬂuoride, beryllium
hydroxide, and beryllium oxide; physical
forms included dust, fume, or mixed (dust
and fume). Individuals from the facility were
assigned, based on jobs worked, the number of
months exposed to three different chemical
forms: nonsoluble beryllium compounds
(beryllium metal and oxide), soluble beryllium
compounds (beryllium ﬂuoride and hydroxide),
and mixed chemical forms. Individuals were
similarly assigned to the number of months
exposed to the three physical forms: dust (beryllium metal, hydroxide, or oxide), fume (beryllium fluoride), and mixed (mixed dust and
fume). This allowed us to evaluate any differences in response due to very small particle size
(fume) or larger particle size (dust or mixed).
We used chi-square tests to compare the
groups (deﬁnite or probable disease vs. sensitized vs. no disease) with respect to discrete
outcomes. ANOVA was used to compare the
groups with respect to continuous outcomes
(age, cumulative, mean, and peak exposure
levels). For the three disease outcome group
comparisons, a screening p-value was set at
0.25, below which the pairwise comparisons
between groups (definite or probable disease
vs. no disease, deﬁnite or probable disease vs.
sensitized, sensitized vs. no disease) were
further investigated. For the discrete outcomes, further chi-square tests were performed on the resulting 2 × k tables. For the
continuous outcomes, the linear contrasts for
these pairwise comparisons were examined in
order to control for multiple comparisons.
For ease of presentation, we also used twosample t-tests to examine pairwise comparisons of the groups. These parametric tests
were followed by the Wilcoxon rank-sum test,
a nonparametric test used to ameliorate the

effects of violations of the assumptions for the
parametric tests (e.g., normal distribution).
We further explored exposure–response
relationships with logistic regression analysis
after adjustment for potential confounders
(smoking, age, other beryllium exposure). In
addition to an analysis where only cases with
complete information were included, an analysis was carried out after multiple imputations
(Rubin 1987) of cumulative and mean exposure values (missing on 65 of 574 individuals).
p-Values are presented as calculated. All
analyses were performed using SAS statistical
software (version 9.1; SAS Institute, Cary,
NC). The results of the spirometry testing are
not reported in this article.

Results
A total of 1,351 individuals were identiﬁed to
have worked at this facility. A summary of the
participation rate for this facility is shown in
Table 2. Approximately one-fourth (24.4%)
of the cohort died before the medical screening began, and another 10.8% could not be
located. Among the 875 individuals located,
160 (11.8%) indicated either that they had
worked for the company that owned the facility but at a different location, or that they had
completed a job application and underwent a
pre-employment physical for work at the
facility but had either not been hired or had
decided not to accept a job at that plant.
Of the remaining 715 former employees,
the participation rate was 63.9% (457 of 715)
for completion of all components of the medical screening and 91.3% (653 of 715) for completion of the questionnaire only. Five hundred
twenty-eight individuals (73.8%) completed at
least the blood and chest radiograph component. Reasons members of the cohort gave for
not participating included that the individual
a) had only worked for a short time; b) felt he
or she was too old and that testing would not
matter; c) did not have any health problems;
d) did not want to jeopardize his or her current
health insurance, especially with no compensation available (at the time the individual was
contacted); and e) felt there was no effective
treatment for beryllium disease.
Table 3 compares the demographics of
medical screening participants with nonparticipants. Medical screening took place from the

Table 3. Demographics of medical screening participants versus those who completed questionnaire only.a
Characteristic
Birth year (mean ± SE)
Male sex (%)
White race (%)
Duration (no.) of years worked (mean ± SE)
Last year worked (mean ± SE)

Completed
questionnaire onlyb

Medical screening
participantsc

1936 ± 1.18
91.8
100.0
5.2 ± 0.85
1969 ± 0.89

1935 ± 0.44
90.8
99.8
8.5 ± 0.40*
1971 ± 0.32*

aSixty-two

individuals who refused to complete questionnaire and medical screening are not included. bIncludes 79 individuals who completed only the questionnaire. cIncludes 574 individuals who completed questionnaires and some part of
medical screening. *p < 0.05.

VOLUME

113 | NUMBER 10 | October 2005 • Environmental Health Perspectives

Beryllium exposure–response study

fall of 1996 through the summer of 2001.
Participants were on average the same age as
the nonparticipants, the same sex and race, last
worked in a more recent year, and worked on
the average 3.3 years longer. Participants were
Table 4. Reason for referral for follow-up testing.
No. (%)
Blood
Two positive BeLPTs
53 (9.2)
Chest radiograph
Profusion > 1/0 per at least two B readers
50 (8.7)
Blood and chest radiographa
7 (1.2)
Total referred
110b (19.1)
aMet criteria
bNine (1.6%)

for both blood and chest radiograph referral.
additional individuals in the cohort met the
study’s criteria for CBD based on testing performed before
the study’s medical screening.

Table 5. Disease categorization of medical test
results (n = 577).
Disease category

No. (%)

Definite CBD
Probable CBD
Possible CBD
Sensitized
Possibly sensitized
No CBD and/or sensitization

32 (5.5)
12 (2.1)
12 (2.1)
40 (6.9)
23 (4.7)
458 (79.4)

Table 6. Predictive power of having unrecognized
CBD documented by bronchoscopy based on
results of BeLPT and chest radiograph.
Total no.
Confirmed
having
CBD cases
bronchoscopy [No. (%)]
Blood
Two positive BeLPTs
Chest radiograph
Profusion > 1/0 at least two
B readers
All zones
Upper zones only
Lower zones only
Blood and chest radiographa
All zones
Upper zones only
Lower zones only

29
22

14 (48.3)
6 (27.3)

4
5
13
5
3
0
2

3 (75.0)
2 (40.0)
1 (7.7)
5 (100.0)
3 (100.0)
NA
2 (100.0)

NA, not applicable.
aMet criteria for blood and chest radiograph referral.

mainly male (91%), and almost all white.
Seventy percent had ever smoked cigarettes.
Among the 577 individuals that were
tested for beryllium, 110 were referred for follow-up testing at the Hospital of the
University of Pennsylvania (Table 4). In addition to the 110 referred, 9 individuals from
the facility had previously been diagnosed at
the University of Pennsylvania with CBD. All
577 individuals, including the 9 previously
diagnosed with CBD, were categorized per the
criteria in Table 1. The results of this classiﬁcation are shown in Table 5. Of the cohort,
7.6% (44) had probable or definite CBD,
2.1% (12) had possible CBD, 6.9% (40) were
sensitized to beryllium, and 4.0% (23) were
possibly sensitized.
Table 6 shows the predictive power of
having unrecognized CBD documented by
bronchoscopy based on the results of the
screening tests performed. Having two positive BeLPTs and scarring on the chest radiograph, involving either all zones or the lower
zones only, had the highest predictive value
for the development of CBD (100%). In
descending order for the other combination of
tests, the predictive values for CBD were scarring on the radiograph in all zones with negative BeLPT (75%), positive BeLPT (48.3%),
scarring in the upper zones with negative
BeLPT (40%), and scarring on the chest
radiograph just in the lower zones (7.7%).
There were 33 cases of definite/probable
CBD among production workers, 5 among
clerical/office workers, 3 in engineers, 1 in a
supervisor/inspector, 1 in a laboratory worker,
and 1 in an industrial hygiene technician.
There were 27 cases of sensitization among
production workers, 10 among clerical/ofﬁce
workers, 2 among engineers, and 1 in a nurse.
Table 7 shows the occurrence of definite
and probable CBD and sensitization by first
decade worked, last decade worked, and duration of years worked. The mean year of first
exposure for deﬁnite/probable CBD was 1963,
for sensitized cases it was 1965, and for the

normal group it was 1964. Further, the mean
year last exposed for deﬁnite/probable, sensitized, and normal individuals was 1973, 1968,
and 1971, respectively. The mean duration of
exposure for deﬁnite/probable, sensitized, and
normal individuals was 9.4 years, 2.7 years,
and 8.7 years, respectively.
Tables 8–12 show the occurrence of deﬁnite and probable CBD and sensitization by
the peak, average, and cumulative exposure
metric, by chemical and physical form of
beryllium and the OSHA (2005) standard of
2 µg/m3 and the DOE (1999) standard of
0.2 µg/m3. Individuals who were sensitized
had a lower total cumulative and peak exposure (Table 8), lower nonsoluble cumulative
and average exposure (Table 11), and lower
dust and mixed exposure (Table 10).
Individuals with CBD had a lower soluble
(Table 9) and fume exposure (Table 10). The
mean beryllium exposure levels for the DWA
categories in Table 11 were 0, 1.23, and
8.95 µg/m3, respectively and in Table 12 were
0.14, 1.19, and 4.76 µg/m3, respectively.

Discussion
The prevalence of CBD and sensitization to
beryllium in former workers at this beryllium
production facility in eastern Pennsylvania was
high: 7.6% with CBD, 6.9% with sensitization, 2.1% with possible CBD, and 4.0% with
possible sensitization. This facility operated
from 1957 to 1978. Representative exposure
estimates for tasks ranged from 0.9 to
84.0 µg/m3 in the 1960s, although most timeweighted averages were below the OSHA
(2005) standard of 2 µg/m3, ranging from 1.1
to 2.5 µg/m3. Exposure estimates in the 1970s
were lower, with representative tasks ranging
from 0.5 to 16.7 µg/m3 and time-weighted
averages ranging from 0.7 to 3.5 µg/m3.
The 14.5% prevalence of CBD and sensitization in the cohort we studied contrasts with
overall prevalence reports of 3.3% among
nuclear workers from Rocky Flats (Stange et al.
2001), 1.8–5.9% from beryllium ceramics

Table 7. Development of definite/probable CBD and sensitization by decade of first and last exposure and duration of exposure.
Disease outcome
Definite/probable CBD
Sensitization
Normal

Decade of first exposure [No. (%)]
1950s
1960s
1970s
14 (34)
7 (18)
112 (27)

17 (41)
22 (56)
222 (54)

10 (24)
10 (25)
75 (18)

1950s

Decade of last exposure [No. (%)]
1960s
1970s
1980s

3 (8)
1 (3)
26 (7)

8 (21)
20 (57)
126 (33)

22 (56)
14 (40)
177 (46)

6 (15)
0 (—)
58 (15)

<1

Duration of exposure (years) [No. (%)]
1 to < 5
5 to < 15
≥ 15

10 (24)
9 (23)
70 (17)

8 (20)
19 (49)
136 (33)

11 (27)
9 (23)
107 (26)

12 (29)
2 (5)
99 (24)

For the decade of first exposure, p = 0.03 for sensitization vs. normal. For the decade of last exposure, p = 0.03 for sensitization vs. definite/probable and p = 0.008 for sensitization vs. normal. For the duration of exposure, p = 0.008 for definite/probable vs. sensitization and p = 0.03 for sensitization vs. normal.

Table 8. Development of definite/probable CBD and sensitization by average cumulative, average mean, and peak exposure (± SE).
Disease outcome
Definite/probable CBD
Sensitization
Normal

No. of
individuals

Mean cumulative exposure
(µg-year/m3)

40
37
377

181 ± 29
100a ± 23
209 ± 16

Mean exposure
(days)
3,483 ± 550
1,934b ± 55
3,359 ± 176

Mean average exposure
(µg/m3)

Mean peak exposure
(µg/m3)

8.7 ± 0.8
7.1 ± 0.9
8.3 ± 0.3

81 ± 14
53c ± 14
87 ± 13

ap = 0. 03 for sensitization vs. definite/probable, and p = 0. 0003 for sensitization vs. normal. bp = 0.047 for sensitization vs. definite/probable, and p = 0.02 for sensitization vs. normal. cp =
0. 01 for sensitization vs. normal.
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manufacturing (Kreiss et al. 1993b, 1996), and
4.6% from a beryllium production facility
(Kreiss et al. 1997). Our overall prevalence is
similar to the prevalence reports for more
highly exposed subgroups from these studies,
such as machinists (Kreiss et al. 1996). Our
higher overall prevalence rate reﬂects both the
level and the widespread exposure to beryllium
in the facility we studied, where 11 deﬁnite/
probable cases occurred among nonproduction workers such as clerical, supervisory, and
engineering staff and 13 sensitization cases
occurred in clerical/office personnel. Our
mean and range of cumulative exposure,
which was 199.25 µg-year/m3 (0.0–3970.61
µg-year/m3, are appreciably higher than estimates reported in other studies: 6.09
µg-year/m3 (0.15–10.64 µg-year/m3) (Kelleher
et al. 2001), 1.35 µg-year/m3 (estimated range,
0–6.41 µg-year/m3) (Viet et al. 2000), and no
mean provided (estimated range, 0.9–41.2 µgyear/m3) (Henneberger et al. 2001). An additional factor that probably contributes to the
higher prevalence of CBD in our cohort is the
long latency since last exposure, which would
have allowed a higher proportion of individuals
who were sensitized to progress on to CBD
than in other cohorts that have been studied
(Newman et al. 2005). Most previous prevalence studies of beryllium-exposed workers
have been of current employees (Henneberger
et al. 2001; Kelleher et al. 2001; Kreiss et al.
1996), or they have included former workers
(Stange et al. 2001) but have not presented
the results separately for current and former
workers. One study similar to ours only had
formerly exposed individuals (Kreiss et al.
1993b). This latter study, unlike ours, found
no individuals with sensitizations alone without CBD. This would suggest that the higher
prevalence of CBD in our study population
was not solely related to the long latency since

last exposure because we would have expected
a lower rate of sensitization alone without
CBD if increased prevalence of CBD was
solely caused by the long latency.
Despite the fact that there is an overall
increase of beryllium disease in working populations with higher exposure to beryllium,
investigators have been unable to show a clearcut exposure response between air concentrations of beryllium and CBD or sensitization
(Henneberger et al. 2001; Kelleher et al. 2001;
Viet et al. 2000). This has led researchers to
examine the possible role of particulate size
(Kelleher et al. 2001; McCawley et al. 2001)
and skin exposure (Tinkle et al. 2003).
We found no difference in duration of
exposure for individuals with CBD versus
those who had no evidence of beryllium disease, but we did ﬁnd that those who were sensitized had begun work later, last worked
longer ago, and had a shorter duration of
exposure than did those with CBD or those
who tested normal (Table 7). This difference
for individuals with sensitization was also true
for cumulative and peak exposure (Table 8),
cumulative mixed and cumulative and mean
nonsoluble exposure (Table 9), cumulative
and mean dust, and cumulative mixed exposure (Table 10). On the other hand, cumulative and mean soluble and cumulative and
mean soluble fume exposures were lower for
CBD (Table 10).
In sum, we either found no exposure
response or the signiﬁcant exposure responses
we did ﬁnd were in the opposite direction than
expected, with individuals with CBD or sensitization having less estimated exposure than
those with no beryllium disease. The risk of
CBD compared with sensitization if a person’s
mean exposure was below the current DOE
(1999) permissible level of 0.2 µg/m3 was less
than if their mean level was > 0.2 µg/m3 but

below the current OSHA (2005) permissible
exposure level of 2 µg/m3 (Table 11). However,
only being exposed to beryllium less than either
the DOE or the OSHA time-weighted average
did not protect a worker from the development
of CBD or sensitization. There were only two
people in the cohort whose highest level of
exposure was never above the 0.2 µg/m3 DOE
standard. CBD and sensitization occurred even
if the highest level of exposure was never
greater than the 2 µg/m3 OSHA standard, and
our data would suggest that peak exposure levels > 0.2 µg/m3 were as harmful as even higher
peak exposure levels > 2 µg/m3 (Table 12).
A possible explanation for the failure to
find an association between increased beryllium disease and sensitization and increased
levels of exposure is that this analysis did not
consider the role of genetic predisposition to
both sensitization and disease. Because the
genetic marker glu69 on HLA-DPB1 has
been associated with 80–90% of cases of both
CBD and sensitization, a better control group
for this analysis would be HLA-DPB1 glu69–
positive individuals who did not have CBD or
sensitization. We have recently been funded to
test our population for this marker and thus
will eventually be able to determine the interaction of exposure and genetic predisposition.
The finding of higher working lifetime
beryllium exposures in those with CBD compared with those who are just sensitized suggests that the body burden of beryllium might
relate to the severity of disease in those with a
genetic predisposition. Our ﬁnding that sensitized individuals compared with individuals
with CBD had a higher exposure to beryllium
in a soluble form and to fumes of beryllium
supports this hypothesis (in this facility soluble
beryllium and fume is practically equivalent,
r = 0.94). Presumably the soluble forms of
beryllium would be more likely to be mobilized

Table 9. Development of definite/probable CBD and sensitization by chemical form of beryllium, mixed, nonsoluble, and soluble: mean cumulative, mean average,
and mean peak exposure levels.

Disease outcome

No.

Cumulative
(µg-year/m3)

Definite/probable CBD
Sensitization
Normal

40
37
377

50
20c
49

Mixed
Mean
(µg/m3)

Peak
(µg/m3)

Cumulative
(µg-year/m3)

3.7
2.3
3.4

2.1
4.4
3.5

126
61d
128

Nonsoluble
Mean
(µg/m3)
7.6
5.4e
7.4

Peak
(µg/m3)

Cumulative
(µg-year/m3)

Soluble
Mean
(µg/m3)

Peak
(µg/m3)

4.6
2.8
4.5

5.8a
19
26

0.8b
2.3
1.6

2.1
4.4
3.6

ap < 0.0001 for definite/probable vs. normal. bp = 0.02 for definite/probable vs. normal. cp = 0.0005 for sensitization vs. normal. dp = 0.04 for sensitization vs. definite/probable, and p = 0.003
for sensitization vs. normal. ep = 0.02 for sensitization vs. normal.

Table 10. Development of definite/probable CBD and sensitization by physical form of beryllium, dust, fume, and mixed: mean cumulative, mean average, and
mean peak exposure levels.

Disease outcome

No.

Cumulative
(µg-year/m3)

Definite/probable CBD
Sensitization
Normal

40
37
377

128
66c
138

Dust
Mean
(µg/m3)

Peak
(µg/m3)

Cumulative
(µg-year/m3)

Fume
Mean
(µg/m3)

Peak
(µg/m3)

7.4
5.1d
7.1

4.6
3.5
5.4

4a
17
20

0.7b
2.3
1.4

0.3
3.1
1.3

Cumulative
(µg-year/m3)
49
17e
46

Mixed
Mean
(µg/m3)

Peak
(µg/m3)

3.6
2.4
3.3

2.1
4.4
3.5

ap = 0.0002 for definite/probable vs. normal. bp = 0.03 for definite/probable vs. normal. cp = 0.0021 for sensitization vs. normal. dp = 0.009 for sensitization vs. normal. ep = 0.0004 for sensitization
vs. normal.
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and eliminated and result in a lower body burden of beryllium compared with a similar exposure to insoluble beryllium.
Individuals who have recently converted
their PPD (puriﬁed protein derivative) skin test
for tuberculosis to positive may, after treatment, revert to a negative PPD (Tager et al.
1985). Thus, with decreasing or elimination of
the antigen, the cellular immune response (i.e.,
PPD reaction) may fade or be eliminated.
Because the PPD reaction is similar to BeLPT,
this suggests that a decreased immune response
to beryllium may occur in individuals with a
lower body burden of beryllium (i.e., antigen).
Thus, a reduced immune response to beryllium may account for the association of beryllium sensitization with a lower body burden of
insoluble beryllium or predominantly soluble
beryllium exposure compared with individuals
with CBD. An alternative explanation that less
soluble beryllium exposure is confounded by
elevated levels of other forms of beryllium is
not supported by analyzing potential correlations between levels of exposures to the different forms of beryllium.
Other researchers have suggested the
importance of skin exposures to the development of beryllium disease. We have no data
to directly address whether skin exposure is of
importance in the development of beryllium
disease in this cohort. However, others have
hypothesized that small particle size increases
the likelihood of both inhalation and skin
absorption and exposure (McCawley et al.
2001). Our data showed the opposite results
with reduced levels of exposure to fume,
which would be the smallest particle size form
of exposure that occurred in this facility, and
CBD (Table 10).
A limitation of our study is the uncertainty
in the exposure estimates. The exposure metrics
developed for study participants were based on
relatively sparse data, with interpolation from
measurement data for years when no data were
available. Major gaps in the data were associated
with the mid-1960s and from 1977 to 1981.
Exposure estimates for the earlier time period
were based on measurements in preceding or

succeeding years; for the later time period, estimates for the mid-1970s were extended into
the later years. These decisions were based on
plant history and conversations with long-term
workers. All interpolation was accomplished
using preestablished rules and was independent
of any knowledge of disease status. The use of
professional judgment like this is often required
in retrospective exposure assessment studies.
Because the exposure estimates were created for
jobs and tasks, without knowledge of a work
history or disease status, it is likely that this misclassiﬁcation would be nondifferential, attenuating any ability to detect exposure–response
relations (Checkoway et al. 1991; Copeland
et al. 1977).
A further limitation relates to the effect of
nonparticipants on study results. The overall
participation rate was high and nonparticipants
were generally similar to participants except
their duration of exposure was less. However, it
is possible that the 11% of the total cohort that
did not participate had a lower rate of CBD
because asymptomatic individuals might be
less motivated to participate. On the other
hand, the 24% of the cohort who were
deceased at the initiation of our study and the
11% we could not locate might be expected to
have a higher prevalence of disease.
A third limitation of our study is that we
used a single laboratory for the blood lymphocyte testing for beryllium in a one-time screening. It has recently been reported that the use
of a single laboratory results in false negative
results of 20–30% (Stange et al. 2004).
Because radiographs were part of our screening, we would expect the false negative rate for
CBD to be lower than the potential false negative rate for sensitization. Because our cohort
was no longer exposed to beryllium, it is less
likely that repeat screening will identify additional cases of CBD or sensitization, as has
been shown in currently exposed cohorts
(Newman et al. 2001).
The participation level of individuals who
warranted more extensive testing after the
initial screening is another limitation of this
study. Only 56 of the 110 (51%) individuals

Table 11. Development of definite/probable CBD and sensitization by the American Conference of
Governmental and Industrial Hygienists notice of intended change, current OSHA, and DOE DWA threshold
levels.
Disease outcome
Definite/probable CBD
Sensitization
Normal

0 to < 0.02
1 (7)
2 (14)
11 (79)

Mean DWA exposure (µg/m3) [n (%)]
0.02 to < 0.2
0.2 to < 2
0 (0)
0 (0)
0 (0)

4 (17)
2 (8)
18 (75)

≥2
35 (8)
33 (8)
348 (84)

Table 12. Development of definite/probable CBD and sensitization by highest exposure.
Disease outcome
Definite/probable CBD
Sensitization
Normal

Environmental Health Perspectives

0 to < 0.2

Highest exposure level (µg/m3) [n (%)]
0.2 to < 2

≥2

0 (—)
0 (—)
2 (100)

18 (9.3)
19 (9.8)
157 (80.9)

22 (8.5)
18 (7.0)
218 (84.5)
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who screened positive by radiograph or BeLPT
elected to have a bronchoscopy. Participation
in more extensive testing was similar in those
with positive radiographs (47%) and those
with abnormal positive BeLPT only (57%).
The lack of a biopsy and broncholavage in half
of the individuals who were positive on the
initial medical screening means we may have
misclassified individuals into the definite/
probable CBD and sensitization groups. This
misclassiﬁcation would decrease the likelihood
of ﬁnding an exposure–response or other relationship with CBD or sensitization. To minimize misclassiﬁcation errors, we excluded cases
classiﬁed as possible CBD or possible sensitization from both the disease and normal groups
during analysis. However, we included four
individuals classified as CBD because of a
diagnosis at the University of Pennsylvania
before our study, although these individuals
never had evidence of sensitization in their
bronchial lavage fluid or blood. We are not
aware of any reason how misclassification
could cause the inverse relationship between
exposure and disease that we found.
A final limitation is that multiple comparisons were made in Tables 9 and 10.
Adjustments for these multiple comparisons
can be made by tripling the p-value reported,
using the properties of the Bonferroni
inequality. If this were done, a number of the
associations would no longer be statistically
significant in Tables 9 and 10. Given the
consistent direction of the ﬁndings, our conclusions concerning soluble and nonsoluble
forms of beryllium remain unchanged even if
this adjustment were made.
In conclusion, this cohort is a high-risk
group for the development of CBD and sensitization. The development of beryllium disease has continued to occur years after
exposure has ceased. Former beryllium workers and their health care providers need to be
aware of this ongoing risk. A combination of
two positive BeLPTs and an abnormal chest
radiograph on the initial medical screening
was the best predictor of the presence of CBD.
However, there were individuals who had
CBD with an abnormal chest radiograph,
involving all or just the upper lobes, and negative BeLPT (Table 6).
We were unable to show an exposure–
response relationship. The inclusion of genetic
data combined with exposure data may better
deﬁne which individuals in this cohort are at a
particularly high risk of development of CBD
and/or sensitization and may account for the
absence of the typical exposure–response seen
with other environmental or occupational
toxins. We are currently performing molecular
typing of DRB1 and DPB1 alleles on individuals with CBD and sensitization and a sample
of those who tested normal to investigate for a
possible gene–exposure relationship.
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This cohort is a high-risk group for the
development of CBD and sensitization. The
development of beryllium disease has continued to occur years after exposure has ceased.
Former beryllium workers and their health
care providers must be kept aware of this
ongoing risk.
The results of this study show that current
occupational health standards for beryllium
do not provide adequate protection against
the development of CBD or sensitization.
Twenty-four percent of the workforce that
was exposed to beryllium below the current
OSHA (2005) allowable threshold limit value
developed CBD or sensitization. Similar levels
of adverse outcomes (21%) were seen in those
exposed to beryllium below the timeweighted average DOE (1999) guideline of
0.2 µg/m3. Even the more protective timeweighted average of 0.02 µg/m3 proposed by
the American Conference of Governmental
and Industrial Hygienists (2005) did not
eliminate adverse outcomes. The identification of cases of CBD and sensitization in this
population at levels of cumulative exposure
lower than current standards or guidelines
underscores the need to more fully understand the determinants of exposure (e.g.,
peak, physical/chemical form) that may contribute to disease risk, so that these may be
included in standard setting.
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